Aslan Pharmaceuticals Ltd ADR
(ASLN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2020 | 03-2020 | 12-2019 | 09-2019 | 06-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -7,322 | N/A | -46,658 | -17,065 | -11,800 |
| Depreciation Amortization | 151 | N/A | 445 | 360 | 256 |
| Accounts payable and accrued liabilities | -461 | N/A | -3,444 | -3,081 | -1,742 |
| Other Working Capital | -1,519 | N/A | -3,486 | -4,033 | -2,434 |
| Other Operating Activity | 905 | 0 | 27,339 | 3,078 | 2,029 |
| Operating Cash Flow | $-8,247 | $N/A | $-25,803 | $-20,740 | $-13,691 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 0 | N/A | 3 | 1 | 0 |
| Purchase Of Investment | N/A | N/A | 3 | 3 | -33 |
| Investing Cash Flow | $0 | $N/A | $5 | $4 | $-33 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | 3,250 | N/A | N/A |
| Common Stock Issued | N/A | N/A | 14,757 | N/A | N/A |
| Other Financing Activity | -129 | 0 | 1,085 | -179 | -135 |
| Financing Cash Flow | $-129 | $N/A | $19,092 | $-179 | $-135 |
| Beginning Cash Position | 22,203 | N/A | 28,909 | 28,909 | 28,909 |
| End Cash Position | 13,827 | N/A | 22,203 | 7,994 | 15,050 |
| Net Cash Flow | $-8,376 | $N/A | $-6,706 | $-20,915 | $-13,859 |
| Free Cash Flow | |||||
| Operating Cash Flow | -8,247 | N/A | -25,803 | -20,740 | -13,691 |
| Capital Expenditure | N/A | N/A | -3 | -3 | -3 |
| Free Cash Flow | -8,247 | 0 | -25,806 | -20,743 | -13,694 |